As Amgen pursues GIP antagonism, a Novo Holdings-backed biotech does the same, boosting its Series A

Am­gen’s obe­si­ty da­ta are help­ing more than its own stock and in­ter­nal R&D ef­forts.

The biotech, which teased Phase 2 da­ta in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.